載入...
Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database
BACKGROUND AND OBJECTIVE: Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS...
Na minha lista:
| 發表在: | Clin Drug Investig |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7595963/ https://ncbi.nlm.nih.gov/pubmed/32779120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-020-00959-7 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|